Strategic Partnerships Capitalize on recent VA and DoD supply contracts and imminent FDA-cleared Hemastyl deployment to position the company as a preferred partner for government medical programs, veteran care initiatives, and federal healthcare networks seeking advanced wound care solutions.

Expansion Opportunities Leverage upcoming commercial deployment starting May 2026 to pursue hospital systems, trauma centers, long-term care facilities, and clinical networks with high incidences of neuropathic and chronic wounds, offering bundled procurement and training services.

Targeted Segments Focus on peripheral neuropathy patients, diabetics, and high-risk wound populations where Hemastyl demonstrates rapid closure rates, pitching value through reduced amputations, cost savings, and improved patient outcomes to payers and hospital admins.

Clinical & Reimbursement Value Highlight Hemastyl’s 95.5% closure rate across 22 high-risk wounds as a differentiator in clinical presentations, align with reimbursement pathways, and support payer engagement with health economic data and case studies.

Scale & Capabilities Position as a nimble, high-impact supplier with FDA clearance, leveraging a lean team to accelerate sales cycles, while targeting larger medical device distributors and systems integrators to scale distribution and field support.